Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
Salarius Pharmaceuticals, Inc. (“Salarius” or the “Company”) (NASDAQ: SLRX) today announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million before deducting underwriting discounts and commissions and other offering expenses. The offering is comprised of 2,514,335 shares of its common stock (“Common Stock”) and pre-funded warrants to purchase 2,152,331 shares […]